Prurigo Nodularis Treatment Market Analysis

Prurigo Nodularis Treatment Market Analysis

Prurigo nodularis treatment market from the corticosteroids segment is set to amass more than 35.5% business share by 2032. The increasing usage of corticosteroids in the treatment of the given health condition will primarily support segment landscape. Drugs containing corticosteroids help lower bodily inflammation and minimize the occurrence of itching, swelling, and redness. Given these exceptional attributes, corticosteroids are considered a preferred treatment choice for patients with prurigo nodularis, which will drive segmental revenues.
 

Prurigo nodularis treatment market from the prurigo nodularis treatment industry segregates into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment garnered over USD 800 million in 2022. The increasing prevalence of prurigo nodularis has resulted in an elevated demand for a variety of medications, ointments, lotions, and other goods associated with the disease treatment. Retail stores are easily accessible and offer a range of these medications at affordable prices, which may bolster their sales in the foreseeable future.
 

North America prurigo nodularis treatment market held a substantial revenue share over 40% in 2022, backed by the consistent expansion of the aging populace. For instance, the elderly population globally is estimated to grow double fold and cross 1.5 billion by 2050. The greater susceptibility of the elderly to several illnesses may result in increased incidences of prurigo nodularis, which will boost product adoption across North America.